MINODYL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MINODYL (MINODYL).
Minodronic acid inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, thereby preventing protein prenylation and inducing osteoclast apoptosis.
| Metabolism | Not significantly metabolized; eliminated primarily unchanged via renal excretion. |
| Excretion | Renal: 90-95% (primarily as metabolites, ~5% unchanged); Fecal: <5% |
| Half-life | Terminal elimination half-life: 4-5 hours; clinical context: requires twice-daily dosing for sustained antihypertensive effect. |
| Protein binding | Minimal (approximately 10% bound to plasma proteins) |
| Volume of Distribution | Vd: 0.7-1.2 L/kg; distributes extensively into smooth muscle cells, with minimal binding to plasma proteins. |
| Bioavailability | Oral: approximately 90% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes |
| Duration of Action | Oral: 2-6 hours; intravenous: 2-4 hours |
5-10 mg orally twice daily, with or without food.
| Dosage form | TABLET |
| Renal impairment | GFR ≥50 mL/min: no adjustment; GFR 30-49 mL/min: 5 mg once daily; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Weight ≤30 kg: 0.2 mg/kg/day divided twice daily; >30 kg: 5 mg twice daily. |
| Geriatric use | Initiate at 5 mg once daily; titrate cautiously due to increased sensitivity to hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MINODYL (MINODYL).
| Breastfeeding | Minoxidil is excreted in human breast milk; M/P ratio not established. Breastfeeding is not recommended due to potential for adverse effects in the infant, such as hypotension and hypertrichosis. |
| Teratogenic Risk | Minodyl (minoxidil) is pregnancy category C. In first trimester, animal studies show increased fetal resorptions and malformations; no adequate human studies. Second and third trimesters: risk of fetal bradycardia, hypotension, and hypertrichosis following transplacental exposure. |
| Fetal Monitoring |
■ FDA Black Box Warning
Not typically associated with black box warnings; however, severe hypocalcemia and osteonecrosis of the jaw have been reported with bisphosphonates.
| Serious Effects |
["Hypocalcemia","Severe renal impairment (CrCl <35 mL/min)","Inability to stand or sit upright for at least 30 minutes (oral form)"]
| Precautions | ["Hypocalcemia must be corrected before initiation","Renal impairment (creatinine clearance <35 mL/min)","Osteonecrosis of the jaw (especially with dental procedures)","Atypical femur fractures","Severe musculoskeletal pain","GI irritation (esophageal ulceration if oral)"] |
Loading safety data…
| Monitor maternal blood pressure, heart rate, and electrolytes. Fetal monitoring includes ultrasound for growth, amniotic fluid index, and fetal well-being assessments (e.g., non-stress test, biophysical profile) due to risk of placental insufficiency. |
| Fertility Effects | Minoxidil has no known direct effects on fertility. However, uncontrolled hypertension during pregnancy may impair placental perfusion and affect fertility outcomes. |